[关键词]
[摘要]
感染性角膜炎(IK)是全球重要的致盲性眼病,早期诊断及治疗对改善预后及减轻经济负担至关重要。文章总结了IK诊断及治疗方式的发展,以期为临床诊治提供新思路。在诊断方面,除传统微生物培养与共聚焦显微镜等外,分子诊断技术如高通量测序(NGS)和CRISPR、纳米技术系统显著提升了多重病原体检测的灵敏度与特异性,尤其适用于混合感染与罕见病原体的鉴定。治疗上,面对日益严峻的耐药性问题,纳米技术、生物活性敷料等新型递药系统通过增强药物渗透性与滞留性,显著提高抗菌效果; 免疫调节和光动力治疗则能有效控制炎症反应改善预后; 中西医结合治疗、微生物群疗法在降低复发率上展现出明显优势; 干细胞疗法为严重角膜损伤的修复提供了新希望; 基因治疗则通过基因编辑或基因的转导,从根源上增强角膜防御能力并减少治疗的副作用。
[Key word]
[Abstract]
Infectious keratitis(IK)is a major blinding eye disease worldwide. Early diagnosis and treatment are crucial for improving prognosis and reducing the economic burden. This article reviews advances in the diagnosis and treatment of IK, aiming to provide new insights for clinical management. In terms of diagnosis, in addition to conventional methods such as microbial culture and confocal microscopy, molecular diagnostic technologies—including high-throughput sequencing(NGS), CRISPR, and nanotechnology-based systems—have significantly enhanced the sensitivity and specificity of multiplex pathogen detection. These approaches are particularly valuable for identifying mixed infections and rare pathogens. Regarding treatment, in response to the growing challenge of drug resistance, novel drug delivery systems employing nanotechnology and bioactive dressings have markedly improved antibacterial efficacy by enhancing drug penetration and retention. Immunomodulatory therapy and photodynamic therapy effectively control inflammatory responses and improve outcomes. Integrated traditional Chinese and Western medicine, as well as microbiome-based therapies, have demonstrated significant advantages in reducing recurrence rates. Stem cell therapy offers new hope for repairing severe corneal damage, while gene therapy—through gene editing or transduction—strengthens the innate defense mechanisms of the cornea and reduces treatment-related side effects.
[中图分类号]
[基金项目]